iCo-007 is a drug which targets something called C-Raf kinase and we are testing its effectiveness in diabetic blindness, otherwise known as diabetic macular edema (DME). Over 20% of diabetics suffer from visual impairment. We believe that there is great potential for differentiation of this product in that the drug targets other factors potentially involved in the disease process – many patients are not responding well to the one approved drug on the market. iCo-007 also displayed a good safety profile in our earlier Phase 1 study and at our current study mid-point. As an example, competition to us, including steroid use, has been known to cause glaucoma and cataract formation. Additionally iCo-007 appears to have a very long treatment effect, and is cheap to manufacture.
iCo-008 addresses orphan or smaller markets such as vernal and atopic conjunctivitis (VKC, AKC) but these markets are poorly addressed by current treatments such as cyclosporine and steroids. It is a very targeted antibody supported by very strong scientific literature and has a clinical history in 126 patients. Recent literature has indicated it may also be considered as a potential candidate in the development of a third wave of products for wet age-related macular degeneration.
Oral Amphotericin B is a non-core asset but is both a delivery platform for highly insoluble products and a reformulation of a potent generic antifungal drug. Recently we have received new patents for this candidate and platform in several countries. Gilead has a product in this arena which historically has sold hundreds of millions of dollars per annum but it is limited to acute settings and an IV line, whereas we are developing an oral version that broaden the number of potential treatment indications without infusion-related side effects.
